The effect of zoledronic acid on the fracture risk in men with osteoporosis

Journal of Endocrinological Investigation

Volumn 37, Issue 3, 2014, Pages 229-232

  Spiegel, R ^a   Nawroth, P P ^a   Kasperk, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bisphosphonates; Comparative studies; Fractures; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CITRATE POTASSIUM; CORTICOSTEROID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; TESTOSTERONE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

BONE DENSITY; BONE TURNOVER; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HYPOGONADISM; MALE; OSTEOPOROSIS; POSTMENOPAUSE; SHORT SURVEY; SPINE FRACTURE; FRACTURES, BONE; RISK ASSESSMENT;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84900553681     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-013-0038-5     Document Type: Short Survey

References (26)

1. Boonen S, Reginster JY, Kaufman JM et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714-1723
2. Jehle S, Hulter HN, Krapf R (2013) Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 98:207-217
3. Boonen S, Lorenc RS, Wenderoth D et al (2012) Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone 51:383-388
4. Adachi JD, Lyles K, Boonen S et al (2011) Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial. Calcif Tissue Int 89:427-433
5. Boonen S, Orwoll E, Magaziner J et al (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59:2084-2090
6. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
7. Boonen S, Orwoll ES, Wenderoth D et al (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719-725
8. Orwoll ES, Miller PD, Adachi JD et al (2010) Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239-2250
9. Orwoll ES, Binkley NC, Lewiecki EM et al (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970-976
10. Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
11. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR et al (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335-1344
12. Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metabol 86:5252-5255
13. Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24:110-113
14. Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242-247
15. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 348:1535-1541
16. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
17. Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65-78
18. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 344:333-340
19. Tarner IH, Erkal MZ, Obermayer-Pietsch BM et al (2012) Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany. Exp Clin Endocrinol Diabetes 120:517-523
20. Soucek O, Lebl J, Zapletalova J et al (2013) Bone geometry and volumetric bone density at the radius in patients with isolated SHOX deficiency. Exp Clin Endocrinol Diabetes 121:109-114
21. Bernecker C, West TB, Mansmann G et al (2012) Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature. Exp Clin Endocrinol Diabetes 120:125-127
22. Glüer CC, Marin F, Ringe JD, et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of teh EuroGIOPs trial. J Bone Miner Res. doi:10.1002/jbmr. 1870. [Epub, ahead of print]
23. Toelle P, Peterli R, Zobel I et al (2012) Risk factors for secondary hyperparathyreoidism after bariatric surgery: a comparison of 4 different operations and of vitamin D-receptor-polymorphism. Exp Clin Endocrinol Diabetes 120:629-634
24. Kasperk C (2013) Zweckmäßige medikamentöse Therapie der Osteoporose. KVBW Verordnungsforum
25. Zhang L, Yang M, Liu D et al (2012) The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 120:361-366
26. Walker MD, Cusano NE, Sliney J Jr, et al (2012) Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine. [Epub, ahead of print]